Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

Performances in N.Y.C. Advertisement Supported by Critic’s Pick Vikingur Olafsson and Yuja Wang appeared at Carnegie Hall with a unified approach to works by Schubert, John Adams, Rachmaninoff ...

Wang Xingxing, the robotics aficionado who founded China’s industry-leading Unitree Robotics, made headlines when the 35-year-old was seated in the front row at President Xi Jinping’s high ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for alpha-1 antitrypsin ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

In a response to the US SEC decision Sanofi neither admitted nor denied any wrongdoing, but confirmed it will pay $25.2 million and agreed to a two-year period of self-reporting on effectiveness ...